肉芽肿性多血管炎

Finkielman JD, Merkel PA, Schroeder D, et al; WGET Research Group. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med. 2007 Nov 6;147(9):611-9.

• 摘要

Mukhtyar C, Guillevin L, Cid MC, et al; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009 Mar;68(3):310-7.

• 全文
• 摘要

Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003 Jul 3;349(1):36-44.

• 全文
• 摘要

De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005 Aug;52(8):2461-9.

• 全文
• 摘要

Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32.

• 全文
• 摘要

Hiemstra TF, Walsh M, Mahr A, et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010 Dec 1;304(21):2381-8.

• 摘要

Flossmann O, Berden A, de Groot K, et al; European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011 Mar;70(3):488-94.

• 摘要

1.  Cotch MF, Hoffman GS, Yerg DE, et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum. 1996 Jan;39(1):87-92.

• 摘要

2.  Mohammad AJ, Jacobsson LT, Mahr AD, et al. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford). 2007 Aug;46(8):1329-37.

• 全文
• 摘要

3.  Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum. 2000 Nov;43(11):2481-7.

• 全文
• 摘要

4.  Knight A, Ekbom A, Brandt L, et al. Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001. J Rheumatol. 2006 Oct;33(10):2060-3.

• 摘要

5.  McKinney EF, Willcocks LC, Broecker V, et al. The immunopathology of ANCA-associated vasculitis. Semin Immunopathol. 2014 Jul;36(4):461-78.

• 全文
• 摘要

6.  Knight A, Sandin S, Askling J. Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease. Arthritis Rheum. 2008 Jan;58(1):302-7.

• 全文
• 摘要

7.  Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012 Jul 19;367(3):214-23.

• 全文
• 摘要

8.  Mahr AD, Neogi T, Merkel PA. Epidemiology of Wegener's granulomatosis: lessons from descriptive studies and analyses of genetic and environmental risk determinants. Clin Exp Rheumatol. 2006 Mar-Apr;24(2 Suppl 41):S82-91.

• 摘要

9.  Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994 Jan 1;120(1):12-7.

• 摘要

10.  van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985 Feb 23;1(8426):425-9.

• 摘要

11.  Sneller MC. Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum. 2005 Jan;52(1):1-5.

• 全文
• 摘要

12.  Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488-98.

• 摘要

13.  Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005 Jan 27;352(4):351-61.

• 全文
• 摘要

14.  Finkielman JD, Merkel PA, Schroeder D, et al; WGET Research Group. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med. 2007 Nov 6;147(9):611-9.

• 摘要

15.  Veerysami M, Freeth M, Carmichael AR, et al. Wegener's granulomatosis of the breast. Breast J. 2006 May-Jun;12(3):268-70.

• 摘要

16.  Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990 Aug;33(8):1101-7.

• 摘要

17.  Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11.

• 摘要

18.  Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J. 1958 Aug 2;2(5091):265-70.

• 全文
• 摘要

19.  Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med. 1971 Dec 30;285(27):1493-6.

• 摘要

20.  Mukhtyar C, Guillevin L, Cid MC, et al; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009 Mar;68(3):310-7.

• 全文
• 摘要

21.  Langford CA, Talar-Williams C, Barron KS, et al. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum. 1999 Dec;42(12):2666-73.

• 全文
• 摘要

22.  Jayne DR, Gaskin G, Rasmussen N, et al; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007 Jul;18(7):2180-8.

• 全文
• 摘要

23.  Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003 Jul 3;349(1):36-44.

• 全文
• 摘要

24.  De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005 Aug;52(8):2461-9.

• 全文
• 摘要

25.  Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012 Jun;71(6):955-60.

• 摘要

26.  National Institute for Health and Care Excellence. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. Mar 2014 [internet publication].

• 全文

27.  Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32.

• 全文
• 摘要

28.  Jones RB, Tervaert JW, Hauser T, et al; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15;363(3):211-20.

• 摘要

29.  Walsh M, Merkel PA, Mahr A, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken). 2010 Aug;62(8):1166-73.

• 全文
• 摘要

30.  Hiemstra TF, Walsh M, Mahr A, et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010 Dec 1;304(21):2381-8.

• 摘要

31.  Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014 Nov 6;371(19):1771-80.

• 摘要

32.  Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum. 1996 Oct;39(10):1754-60.

• 摘要

33.  Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017 Aug;69(8):1521-37.

• 全文
• 摘要

34.  De Groot K, Harper L, Jayne DR, et al; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009 May 19;150(10):670-80.

• 摘要

35.  Langford CA, Monach PA, Specks U, et al; Vasculitis Clinical Research Consortium. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis. 2014 Jul;73(7):1376-9.

• 摘要

36.  Little MA, Nightingale P, Verburgh CA, et al; European Vasculitis Study (EUVAS) Group. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010 Jun;69(6):1036-43.

• 摘要

37.  Mohammad AJ, Jacobsson LT, Westman KW, et al. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009 Dec;48(12):1560-5.

• 摘要

38.  Walsh M, Faurschou M, Berden A, et al; European Vasculitis Study Group. Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1571-6.

• 摘要

39.  Seo P, Min YI, Holbrook JT, et al; WGET Research Group. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2005 Jul;52(7):2168-78.

• 全文
• 摘要

40.  Flossmann O, Berden A, de Groot K, et al; European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011 Mar;70(3):488-94.

• 摘要

41.  Bakthavachalam S, Driver MS, Cox C, et al. Hearing loss in Wegener's granulomatosis. Otol Neurotol. 2004 Sep;25(5):833-7.

• 摘要

42.  Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002 Jul 1;100(1):82-5.

• 全文
• 摘要

43.  Hellmich B, Kausch I, Doehn C, et al. Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide? Ann Rheum Dis. 2004 Oct;63(10):1183-5.

• 全文
• 摘要

44.  Faurschou M, Mellemkjaer L, Voss A, et al. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2015 Aug;54(8):1345-50.

• 全文
• 摘要

45.  de Leeuw K, Sanders JS, Stegeman C, et al. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis. 2005 May;64(5):753-9.

• 全文
• 摘要

46.  Stone JH, Hoffman GS, Merkel PA, et al; International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum. 2001 Apr;44(4):912-20.

• 摘要

47.  Exley AR, Bacon PA, Lugmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997 Feb;40(2):371-80.

• 摘要